modelMolnupiravir
Extends from Pharmacolibrary.Drugs.ATC.J.J05AB18.
Information
| name: | Molnupiravir | |
| ATC code: | J05AB18 | route: | oral |
| compartments: | 1 | |
| dosage: | 800 | mg |
| volume of distribution: | 142 | L |
| clearance: | 59.8 | L/h |
| other parameters in model implementation | ||
Molnupiravir is an oral antiviral prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits replication of SARS-CoV-2, the virus responsible for COVID-19. It is used for the treatment of mild to moderate COVID-19 in adults at risk of progressing to severe disease. It has received emergency use authorization in some regions.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers (median age 25-52 years) after oral administration, single dose, fasting state.
References
Pagliano, P, et al., & Conti, V (2022). The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert opinion on drug discovery 17(12) 1299–1311. DOI:10.1080/17460441.2022.2153828 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36508255
Chawla, A, et al., & Stone, JA (2023). Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clinical pharmacology and therapeutics 113(6) 1337–1345. DOI:10.1002/cpt.2895 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37017631
Nakamura, K, et al., & Uemura, N (2022). A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19. Clinical and translational science 15(11) 2697–2708. DOI:10.1111/cts.13395 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36053806
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)